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ABSTRACT
Objectives To (1) assess women’s current knowledge 
regarding long- term cardiovascular health after 
hypertensive disorders of pregnancy (2) elicit women’s 
preferred educational content and format regarding health 
after hypertensive disorders of pregnancy.
Design and setting A custom- created online survey 
exploring Australian women’s knowledge about long- 
term health after hypertensive disorders of pregnancy, 
distributed through consumer groups and social media.
Participants 266 women with (n=174) or without (n=92) 
a history of hypertensive disorders of pregnancy.
Primary and secondary outcome measures (1) 
Proportion of women identifying long- term health risks 
after hypertensive disorder of pregnancy using a 10- point 
risk knowledge score with 0–4 ‘low’, 4.1–7.0 ‘moderate’ 
and 7.1–10 ‘high’. (2) Exploration of preferred content, 
format and distribution of educational material post 
hypertensive disorder of pregnancy.
Results Knowledge scores about health after 
hypertensive disorder of pregnancy were moderate 
in groups with and without a history of the disorder. 
Knowledge was highest regarding risk of recurrent 
hypertensive disorders in a subsequent pregnancy, 
‘moderate’ for chronic hypertension and heart attack, 
‘moderate’ and ‘low’ regarding risk of heart disease and 
‘low’ for diabetes and renal disease. Only 36% of all 
participants were aware that risks start within 10 years 
after the affected pregnancy. The majority of respondents 
with a history of hypertensive disorder of pregnancy (76%) 
preferred receiving information about long- term health 
0–6 months post partum from a healthcare provider 
(80%), key organisations (60%), social media (47%) and 
brochures/flyers (43%).
Conclusions Women’s knowledge regarding health risks after 
hypertensive disorder of pregnancy was ‘moderate’, although 
with important disease- specific gaps such as increased risk of 
diabetes. Most women wanted to be informed about their long- 
term health from a healthcare provider.
INTRODUCTION
Hypertensive disorders of pregnancy 
(HDP) include chronic hypertension (CH), 
pre- eclampsia (PE) and gestational hyper-
tension (GH) and complicate 5%–10% of 
pregnancies.1 PE is a multi- system disorder 
characterised by new- onset hypertension 
after 20 weeks’ gestation and involvement 
of one or more other organ systems and/or 
the foetus.2 3 GH is new- onset hypertension 
after 20 weeks’ gestation without any other 
complications. Apart from GH itself being 
considered an adverse pregnancy outcome 
and it carrying an increased risk of progres-
sion to PE,2 3 is not otherwise associated with 
adverse pregnancy outcomes. However, both 
conditions are associated with long- term 
cardiovascular and other chronic disease 
sequelae.4 5 CH is defined as hypertension 
that is confirmed before pregnancy or before 
20 completed weeks gestation, which may 
worsen during pregnancy and/or on which 
PE may be superimposed.2 Globally, cardio-
vascular disease (CVD) is one of the leading 
causes of death in women,6 and for women 
who have experienced an HDP, it is 2–3 
times higher compared with those who did 
Strengths and limitations of this study
 ► Consumer co- created survey exploring health 
knowledge after hypertensive pregnancy.
 ► For the first time survey results include findings from 
women with a history of gestational hypertension as 
well as from women without a history of hyperten-
sive disorder of pregnancy.
 ► Recruitment from groups with potentially greater 
baseline knowledge may bias results, although sub-
stantive knowledge gaps still found.
 ► Although surveys were available in English, Arabic 
and Mandarin, there remains potential suboptimal 
coverage of culturally and linguistically diverse 
groups.
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not.4 7 8 This risk of premature death is present within 
10 years after the affected pregnancy7 9 10 and remains 
after adjusting for the presence of other cardiovascular 
risk factors. There is also an increasing body of recent 
research linking PE and GH with other major chronic 
diseases including chronic kidney disease, end- stage 
kidney disease and type 2 diabetes mellitus.11–14
Both Australian and international societies, including 
the Society of Obstetric Medicine of Australia and New 
Zealand (SOMANZ) and the International Society for 
the Study of Hypertension in Pregnancy (ISSHP), recom-
mend that women and healthcare providers (HCP) are 
provided with information about HDP and later CVD.2 3 
This includes recommending that women have a clinical 
review several months post partum, and regular general 
practitioner follow- up to monitor blood pressure, fasting 
lipids and blood sugar.2 Adopting a healthy lifestyle with 
maintenance of an ideal weight and regular aerobic exer-
cise is emphasised.2 3 The aims of this study were to (1) 
explore Australian women’s current knowledge on the 
topic of long- term CVD health after any HDP, not just PE 
and (2) elicit women’s preferred educational content and 
format regarding health after HDP, as a basis for creating 
tailored information and health advice for women after 
HDP.
METHOD
A national survey of women with and without a history 
of HDP was conducted, using a custom- created, face- 
validated online survey.
Patient and public involvement
As a validated instrument to assess women’s knowledge 
was unavailable, a survey was custom designed. Initially, 
women with a history of HDP, comprising nine volunteers 
from the Postpartum physiology, psychology and paedi-
atric follow- up study (P4 study)15 and Australian Action 
on Pre- eclampsia (AAPEC), were invited to take part in 
group interviews which addressed the possible content 
and design of the survey, tested the survey for face 
validity and provided feedback for improvement. The 
topics discussed during the interviews were sourced from 
findings from a scoping literature review16 and further 
complemented by questions specifically exploring the 
Australian context for women experiencing HDP. Nine 
women participated in the face- validation process and 
commented on content, language, flow, survey structure 
including length, whether the introduction and the risk 
profile proposed for the end of the survey were informa-
tive as well as using appropriate language. Following feed-
back and integration of suggestions from the women, the 
survey was modified until consensus over a final version 
was achieved among study investigators, including the 
consumer representative (LH). The survey was made 
available in English, Arabic and Mandarin.
Data collection
The final survey was targeted at women in Australia, 18 
years and older with a history of pregnancy in the last 3 
years. Women who were currently pregnant were requested 
to only complete the survey if they had no major issues in 
their current pregnancy. Women not currently pregnant 
with pregnancy in the preceding 3 years were eligible 
either if they had experienced HDP (CH, GH or PE) or a 
pregnancy without any serious complications. The online 
survey, using SurveyMonkey, was open from July to August 
2019. Survey distribution occurred through the P4 study 
participants, organisations such as AAPEC, maternity 
consumer groups as well as via the project’s consumer 
representative and social media (Facebook and Twitter) 
including multicultural networks in order to reach Arabic 
and Mandarin speaking communities. A targeted conve-
nience sample was selected. Prior to acknowledging their 
voluntary participation at the commencement of the 
survey, women were presented with an introductory letter 
outlining the details of the study (online supplemental 
appendix 1). Commencement of the survey was then 
taken as consent to participate.
Data collection instrument
The survey for women (online supplemental appendix 1) 
explored demographic details, assessed obstetric history, 
history of HDP and other medical history including 
family history. The survey was tailored to women’s self- 
reported HDP history (GH, PE, CH with or without 
worsening in pregnancy or superimposed PE, no hyper-
tension history), with women given definitions of HDP 
conditions early in the survey to aid their self- report. 
Questions focused on knowledge of risk after pregnancy, 
provision of care and education following birth and what 
information and education women would like to receive. 
Women with a history of GH, PE or CH were asked to 
classify their perceived risk (based on their own lived 
HDP subtype) of experiencing various long- term health 
outcomes as greater, less than or equal to that of a woman 
with a normotensive pregnancy. Women who experi-
enced a normotensive pregnancy were also asked to clas-
sify whether they believed women who had had HDP were 
at greater, lesser or equal risk. The survey included two 
‘distractor’ conditions not known to have an increased 
risk after HDP (breast cancer and seizures) to elicit nega-
tive answers and ascertain whether women could identify 
what they were not at increased risk of after HDP as well 
as what they were at risk of. At survey completion, women 
were provided with a correct risk profile summary and a 
link to further information.
Data analysis
Quantitative survey analysis was undertaken using SPSS 
V.25. Demographic data and responses to individual ques-
tions were analysed descriptively. To examine difference 
in knowledge levels among the targeted subgroups (GH, 
PE, CH in pregnancy, no hypertension history) responses 
regarding HDP and future health risks were compared 
using χ2 testing or likelihood ratio for categorical data 
(as appropriate to subgroup sample size) and one- way 
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analysis of variance (ANOVA) testing for continuous data. 
A p value of <0.05 was considered statistically significant.
A knowledge score was created for the risk matrix 
whereby 1 point was allocated to the correct answer, 0 
for the incorrect answer, 0 for ‘I do not know’ and 0 for 
no answer/left blank. A mean knowledge score for each 
condition/health outcome was calculated and a scale of 
‘low’, ‘moderate’ and ‘high’ knowledge was established. 
The ranking classifications were chosen based on the data 
distribution and were divided into three score categories. 
For each individual condition/health outcome’s mean 
score, ‘low knowledge’ equated to a mean of 0.00–0.40, 
‘moderate knowledge’ was 0.41–0.70 and ‘high knowl-
edge’ a mean of 0.71–1.00. An overall mean score out of 
10 (as there were 10 conditions) was calculated for the 
HDP and non- HDP groups (ie, the HDP group’s knowl-
edge regarding their long- term health risks and the non- 
HDP group’s knowledge regarding the long- term health 
risks of HDP women). This overall score was classified as 
‘low’ ‘moderate’ or ‘high’ using the same mean ranges 
as were used for the individual conditions. Categorical 
analysis for proportions of each knowledge group (‘high’, 
‘moderate’ and ‘low’) was also conducted to provide a 
further perspective.
RESULTS
In total, 308 survey responses were received (figure 1). 
Forty- two were excluded: 40 for discontinuing the survey 
and not answering the question asking about their 
perception of lower/same/higher risk with regards to 10 
health conditions, and two with ‘CH only’ (no worsening 
hypertension or superimposed PE in pregnancy) who 
were excluded due to small numbers. Of 266 included 
responses, 174 (65%) women had a lived experience of 
any HDP (will be known as HDP for reporting purposes) 
and 92 (35%) did not (will be known as non- HDP for 
reporting purposes). The HDP group consisted of 15 
women with GH only (9%), 143 women with PE only 
(82%) and 16 women with CH plus superimposed preg-
nancy hypertension or PE (9%; will be known as CH). Of 
the HDP group, 123 (71%) had their most recent experi-
ence with HDP less than 3 years prior (32% <1 year prior 
and 39% 1–3 years prior).
Most respondents were in the 26–35- year or 36–45- year 
age groups (91%), 89% were of Caucasian ethnicity, 90% 
pursued education beyond secondary school and 96% 
were in a relationship (table 1). HDP women were more 
likely to be Caucasian, to have a history of diabetes, renal 
problems, be overweight and to have at least one addi-
tional cardiovascular risk factor than non- HDP women 
(online supplemental table 1), and less likely to be 
university- educated. Half of all participants were sourced 
through social media (50%), with most of the remainder 
(45%) recruited via the P4 study (8% of HDP women, 
46% of non- HDP women) and AAPEC (35% of HDP 
women).
Average knowledge scores are shown in table 2 and 
detailed results on which these scores are based are 
shown in online supplemental tables 2–11. Overall knowl-
edge of the 10 conditions in the survey was ‘moderate’ 
for both groups (5.6/10 among HDP and 5.2/10 among 
non- HDP, p=0.21), with 33% in both groups having ‘high’ 
overall knowledge and 32% and 40%, respectively having 
‘low’ overall knowledge (online supplemental table 12). 
Women with a history of HDP had ‘high’ knowledge with 
regards to recurrence of HDP in a subsequent pregnancy 
(0.90) and risk of future CH (0.76). The same group 
had ‘moderate’ knowledge regarding increased risk 
Figure 1 Survey inclusion. CH in pregnancy, chronic hypertension worsening in pregnancy and/or with superimposed PE; GH, 
gestational hypertension; HDP, hypertensive disorders of pregnancy; PE, pre- eclampsia.
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of conditions such as heart attack (0.68), heart disease 
(0.68) and stroke (0.63). Women without HDP history 
had ‘high’ knowledge (0.71) for HDP recurrence in a 
subsequent pregnancy. The same group of women had 
moderate knowledge of CH (0.62) and stroke (0.53). 
Lowest knowledge across both groups was around the 
risk of future diabetes (0.25 HDP group and 0.35 for 
non- HDP group). Further ‘low’ scoring conditions were 
peripheral vascular disease (PVD) and renal disease. For 
most conditions HDP women had significantly higher 
knowledge than the non- HDP group. However, the non- 
HDP group were more likely to correctly identify that the 
risk of the two ‘distractor’ conditions, seizures or breast 
cancer, were equal for both groups.
Online supplemental table 13 shows knowledge score 
breakdown by time since pregnancy. In the subgroup of 
HDP women who experienced PE (n=143), average knowl-
edge was similar among women who experienced HDP 
within the last 3 years (5.8/10), compared with those who 
experienced HDP more than 3 years ago (5.7/10). Of the 
HDP women, only 32% were aware that the cardiovascular 
conditions may start manifesting within 10 years after an 
affected pregnancy, compared with 45% of women in the 
non- HDP group (p=0.036). About a third in each group 
(30% HDP, 36% non- HDP) were unsure about timing of 
risk rise/when health conditions manifest (online supple-
mental table 14).
Women with HDP history were asked about their 
personal experience of risk discussion with HCP (table 3 
represents summary of collective HDP data, online supple-
mental table 15 provides all findings by HDP subgroup). 
The most frequent discussions about future health were 
regarding HDP in subsequent pregnancies (45%), risk of 
CH (43%) and ‘no discussion’ (37%). Risk discussions 
were no more likely to have occurred in women with HDP 
less than 3 years ago or over 3 years ago. There were also 













P value HDP vs 
non- HDP
Total N 266 15 143 16 174 92
Age
  18–25 12 (5) 13 6 – 10 (6) 2 (2) 0.16
  26–35 117 (44) 33 48 50 81 (47) 36 (39) 0.25
  36–45 126 (47) 53 42 50 76 (44) 50 (54) 0.10
  45+ 10 (3) – 5 – 7 (4) 3 (3) 0.75
  Prefer not to answer 1 (0) – – – – 1 (1) –
Ethnicity
  Caucasian 236 (89) 93 97 81 165 (95) 71 (77) <0.001
  Asian 23 (9) 7 2 6 5 (3) 18 (20) <0.001
  Other* 7 (3) - 1 13 4 (2) 3 (8) 0.65
Highest educational attainment
  Secondary school 25 (9) 7 14 13 23 (13) 2 (2) 0.003
  Diploma/trade† 69 (26) 33 33 50 60 (35) 9 (10) <0.001
  University degree 171 (64) 60 52 38 90 (52) 81 (88) <0.001
  Prefer not to answer 1 (0) – 1 – 1 (1) – –
  Relationship status
  In a relationship 254 (96) 100 93 88 162 (93) 92 (100) 0.001
  Not in a relationship 11 (4) – 6 13 11 (6) 0 (1)
  Prefer not to answer 1 (0) – 1 – 1 (1) – –
  Recruited to survey via
  P4 newsletter 56 (21) 13 8 6 14 (8) 42 (46) <0.001
  AAPEC 62 (23) 7 40 19 61 (35) 1 (1) <0.001
  Social media 134 (50) 80 52 69 97 (56) 37 (40) 0.02
  Other‡ 14 (5) – 1 6 2 (1) 12 (13) <0.001
*Other: Indigenous Australian (n=1), Polynesian or Maori (n=2), mixed ethnicity (n=4).
†Diploma or trade certificate.
‡Other: friend (n=11), ACM (n=1), Clinic (n=1), maternity consumer group other than AAPEC (n=1).
AAPEC, Australian Action on Pre- eclampsia; ACM, Australian College of Midwives; CH, chronic hypertensionchronic hypertension worsening 
in pregnancy and/or with superimposed PE; GH, gestational hypertension; HDP, hypertensive disorders of pregnancy; PE, pre- eclampsia.
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no statistically significant differences found between HDP 
subgroups about whether future risks were discussed, or 
what types of risk were discussed.
When asked about preferences of the timing of a future 
risk discussion, the majority (76%) of women wanted a 
discussion 0–6 months post partum. The topics most 
women with HDP wished to discuss (table 4) are ‘impact 
on my children from the pregnancy affected by HDP’ 
(73%), ‘signs and symptoms of the conditions’ (67%), 
‘when does risk rise’ (54%) and ‘risk reduction for 
subsequent pregnancy’ (54%). HDP women’s preference 
for receiving information on long- term health after HDP 
is via a medical professional (80%), through key organisa-
tions such as the Australian Heart Foundation (60%) and 
social media (47%).
DISCUSSION
This study found overall, ‘moderate’ knowledge of health 
conditions after HDP among both HDP and non- HDP 
Table 2 Means of risk factor knowledge of women listed by type of HDP
GH n=15 PE n=143 CH n=16 HDP n=174
Non- HDP 
n=92
P value HDP vs 
non- HDP
Chronic hypertension 0.53 0.78 0.81 0.76 0.62 0.02
Diabetes 0.27 0.24 0.31 0.25 0.35 0.12
Renal disease 0.27 0.54 0.69 0.53 0.21 <0.001
Heart attack 0.53 0.69 0.75 0.68 0.52 0.01
Repeat HDP 0.87 0.90 0.94 0.90 0.71 <0.001
Stroke 0.47 0.62 0.81 0.63 0.53 0.14
Heart disease 0.47 0.69 0.75 0.68 0.50 0.005
PVD 0.33 0.50 0.50 0.32 0.45 <0.001
Breast cancer* 0.20 0.52 0.31 0.47 0.65 0.004
Seizures* 0.27 0.29 0.13 0.27 0.44 0.01
Overall mean knowledge score 
(out of 10)
4.2 5.8 6.0 5.6 5.2 0.21
  
*Breast cancer and seizures are distractors within the survey. These were included despite being conditions that women after HDP are not at 
greater risk of.
CH, chronic hypertension worsening in pregnancy and/or with superimposed PE; GH, gestational hypertension; HDP, hypertensive disorders 
of pregnancy; PE, pre- eclampsia; PVD, peripheral vascular disease.
Table 3 Proportion of conditions discussed when addressing future risk (multiple answers collected) within and over 3 years 
since last HDP (summary of collective HDP data)*
Total n=174 N (%) Overall total n=174 N 
(%)
P value <3 years vs >3 
years<3 years >3 years
HDP next pregnancy 55 (45) 24 (47) 79 (45) 0.78
Chronic hypertension 55 (45) 19 (37) 74 (43) 0.37
No discussion 45 (37) 19 (37) 64 (37) 0.93
Lifestyle changes 32 (26) 8 (16) 40 (23) 0.14
Heart attack 22 (18) 7 (14) 29 (17) 0.50
Renal disease 23 (19) 4 (8) 27 (16) 0.07
Stroke 20 (16) 6 (12) 26 (15) 0.45
Peripheral vascular disease 16 (13) 5 (10) 21 (12) 0.56
Cannot remember 6 (5) 2 (4) 8 (5) 0.78
*Table represents frequency of each option; percentages add to over 100% as women were asked to select any/all that applied.
HDP, hypertensive disorder of pregnancy.
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women. Among women with a history of HDP, highest 
knowledge was identified with regards to future risk of 
hypertension and repeat HDP in subsequent pregnan-
cies. Conversely, knowledge of future risk of diabetes 
was low, as was knowledge of the ‘distractor’ conditions 
among HDP women particularly. Diabetes as a future risk 
factor post- HDP has previously not been reported on in 
studies of women’s knowledge, and our findings suggest 
this is an important knowledge gap to address.
Other novel aspects of our study are inclusion of women 
who had a history of GH as well as those with a history of 
PE, and assessing knowledge of non- HDP women’s knowl-
edge. Women after HDP had somewhat higher knowledge 
of most health risks than the non- HDP group, however 
non- HDP group also had better knowledge of some 
aspects such as timing of risk increase. However, both 
groups’ knowledge of the early increase in risk was low, 
adding further concern and reason to address the knowl-
edge gap. When looking at the proportion of participants 
scoring ‘high’, these were equal between the HDP (33%) 
and non- HDP groups (33%), while proportions scoring 
‘low’ were similar enough (32% HDP vs 40% non- HDP) 
to not to show statistical significance. Our scoping review 
in 201916 identified that post- HDP, women have insuffi-
cient knowledge of their long- term risks. By including 
non- HDP women we wanted to explore whether knowl-
edge was similar between the groups, which if so would 
suggest HDP women are not receiving tailored, targeted 
information and/or any information received is not 
translated into knowledge of personal risk after HDP. 
Given women after HDP were not markedly more knowl-
edgeable about their health risks than unaffected women, 
the research- to- practice translational gap is further high-
lighted and suggests women with a lived experience of 
HDP remain underinformed about their increased CVD 
risk.
A further important finding was that many HDP 
women were not made aware of future health risks, with 
37% of HDP women reporting to have had ‘no discus-
sion’ about their increased long- term risk. Women with 
more recent HDP were no more likely than women with 
HDP >3 years ago to report having risks discussed, which 
is concerning. This finding suggests risk discussions 
may not have improved in recent years despite updated 
guidelines emphasising long- term health,2 3 and that the 
extensive evidence regarding long- term implications for 
women after HDP continues to be lost in the translation 
of research to practice. We are exploring reasons for this 
(eg, lack of evidence base in guidelines, lack of provider 
knowledge of guidelines, siloed healthcare with insuf-
ficient handover from maternity care team to primary 
care) in our broader work.
Women’s knowledge after GH has not been previously 
reported as far as we are aware even though GH has 
similar frequency and similar future CVD risk as PE.4 17 
Although only 9% of our sample were GH, this group 
Table 4 HDP women’s preferences for content and distribution of information/education on future risk after HDP (multiple 









Total N 15 143 16 174
Preference of discussion topics*
  Impact on my children from the pregnancy affected by HDP 73 80 63 136 (73)
  Signs and Symptoms of the conditions 80 71 69 124 (67)
  Risk reduction for subsequent pregnancy 40 62 44 101 (54)
  When does the risk rise 40 61 50 101 (54)
  Statistics 40 60 38 98 (53)
  Reducing risk behaviours (diet, exercise, smoking cessation) 40 56 31 91 (49)
  Where to find information 40 51 13 81 (44)
  How to discuss the matter with my healthcare provider 27 40 25 65 (35)
Preference of distribution*
  Medical professionals 73 82 75 140 (80)
  Key organisations 53 61 63 105 (60)
  Social media 40 51 19 82 (47)
  Brochures/flyers 40 45 31 75 (43)
  Online videos 20 24 25 42 (24)
  Podcast/media 13 23 25 39 (22)
*Table represents frequency of each option; percentages add to over 100% as women were asked to select any/all that applied.
CH, chronic hypertension worsening in pregnancy and/or with superimposed PE; GH, gestational hypertension; HDP, hypertensive disorders 
of pregnancy; PE, pre- eclampsia.
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had somewhat lower knowledge than the PE and CH 
groups regarding conditions after HDP (although mostly 
not reaching statistical significance). Over half reported 
receiving no discussion of health risks after GH. Despite 
the small number of women with a history of GH (n=15) 
contributing to the study, this suggests potential substan-
tive knowledge gaps after GH to address in both women 
and HCP.
International studies exploring women’s knowledge 
have predominantly reported limited or no knowledge 
about the link between HDP and CVD,16 though our 
study found overall, ‘moderate’ knowledge of health 
conditions after HDP. The two conditions associated 
with highest knowledge were repeat HDP and risk of 
future hypertension. Findings were similar in Traylor et 
al’s18 survey conducted in the USA, where 146 women 
post- HDP were included (PE n=76, PE with severe 
features n=41, CH=29). Future hypertension and repeat 
HDP were correctly identified by women as risk factors; 
however, this knowledge was mainly reflected in the 
group of women who had experienced PE with severe 
features. In the UK, Brown et al19 (n=12 women attending 
postnatal follow- up clinic) also found that women are 
aware of repeat HDP risks; however, despite postnatal risk 
counselling, perception of hypertension and CVD risk 
was mainly associated with participants who had a family 
history of CVD. More recently in Australia, Hutchesson 
et al20 surveyed 127 women with PE in the 2 years prior, 
finding very high knowledge about future hypertension 
risk (96%, higher than our post- PE findings) and most 
were aware of stroke (67%) and CVD (66%) risks (similar 
to our findings). Over a third of women after PE had ‘no 
discussion’ about future risk in our study. Hutchesson et 
al20 reported over one third of their participants remained 
unaware of increased CVD risks, which is similar to our 
findings. Similarities may be explained by the fact that 
major source of PE participants for both, the Hutchesson 
et al20 survey and ours was the patient support/advocacy 
group AAPEC. Recruitment from this advocacy group 
may also explain a higher post- PE knowledge than other 
studies have reported.
Our study findings resonate with those from similarly 
targeted women in Canada, Portugal, UK, the USA and 
a previous Australian study, all conducted between 2013 
and 2017.16 Therefore, from a global perspective, these 
findings reinforce a persistent and concerning, research 
to consumer gap. With international guidelines, including 
ISSHP,2 specifically targeted to assist HCPs providing care 
to women on an international scale to better manage and 
address health after HDP, this practice gap of knowledge 
transmission to women would be expected to narrow.
Education preferences
Content
Women mostly wanted educational materials to address 
HDP impact on their children, signs and symptoms of 
conditions they are at higher risk of, the timing of when 
their risks rise, and how to best reduce risk of recurrent 
HDP. Similar preferences were expressed by the women 
included in Seely et al’s21 focus group of 20 women after 
PE, with the key concern being the impact the PE preg-
nancy may have had on the health of their children. 
More recently, a UK- based study,22 involving women with 
a history of HDP and HCPs, identified research priorities 
regarding HDP. The top- ranking priority identified was 
the long- term physical and mental health consequences 
of HDP for the woman, baby and family. Other ‘uncer-
tainties’ expressed by participants regarding their lived 
experience of HDP included topics such as diagnosis and 
management in pregnancy, prevention of future compli-
cations, short and long- term consequences of HDP for 
the woman and the baby, prevention of recurrent HDP as 
well as educational needs of HCPs and support for women 
and their families. Our study, with focus on women in 
Australia, suggests that similar uncertainties may benefit 
from being addressed, hence validating the importance 
of our findings.
Format of education and access
Our study identified that women mostly wanted to receive 
information about long- term health after HDP from 
medical professionals. Key organisations who are experts 
on the topic, via social media and through information 
brochures were other acceptable avenues of access to 
information. This is in contrast to Skurnik et al’s23 focus 
group of 14 women after PE, whose preferences for educa-
tional materials about the link between CVD and PE were 
via pamphlets available in doctor’s offices as well as via 
online communities and topical blogs. However, Hird 
et al’s24 participants also expressed preference for HCP 
as their information source, including wanting HCP to 
guide them towards reliable online/external information 
sources rather than encounter irrelevant or potentially 
inaccurate information due to their self- initiated search. 
Hutchesson et al20 report that high knowledge among 
participants was mainly due to the women’s own research 
rather than receiving all possible, relevant information 
from their healthcare provider. Overall, existing studies 
including ours would suggest that although women are 
very open to the use of online sources or information 
packs, their HCP are seen as central to closing their 
knowledge gaps.
Time of risk discussion
An important element to consider when communicating 
about risk with women who have experienced GH or PE 
is the timing of these discussions, as situational factors 
of being a new mother may alter when women are most 
receptive to follow- up. In our study, three- quarters of 
the women preferred this to occur in the first 6 months 
after birth. As well as being their preference, this also 
aligns with the potential benefits of early intervention 
and would allow for addressing knowledge gaps found 
in this study around how soon the risk rises after HDP. 
Addressing future risk early but not immediately is also 
supported by Brown et al’s study of women after PE, where 
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participants suggested that 6 months post partum was the 
timeframe where they felt they had transitioned into a 
more comfortable stage of parenting and were able to 
focus more on themselves again.19
Strengths and limitations
The survey was co- created via a formalised process of 
seeking input and feedback on the usability, language and 
content from women who have previously experienced 
HDP. Although face- validation is a subjective process, 
involving consumers with a history of HDP gives added 
value to the survey.
Our knowledge score is both a strength, as it allows for 
a summary of findings across all the conditions and risks, 
and a limitation, as assigning cut- points for knowledge 
ranking is an arbitrary designation. Having included the 
distractor conditions (breast cancer and seizures) may 
also have altered the overall score. While women are more 
likely to experience seizures during a pregnancy compli-
cated by HDP compared with non- HDP women, the 
long- term risk of seizures is similar for both groups. Simi-
larly, the association of HDP and future increased risk of 
cancer (including breast cancer) has been examined in a 
systematic review and meta- analysis, however proven not 
to be associated with increased future risks after HDP.25 
Distractor inclusion may well have lowered overall knowl-
edge score, for example, women believing that after HDP 
they are at more risk of ongoing seizures since this is a risk 
during PE- affected pregnancy. However, we believe inclu-
sion of distractors and assessment of women’s response to 
them is valid, as it is important for women to not incor-
rectly believe they are at increased risk of more condi-
tions than they are, as well as having knowledge of their 
increased cardiovascular risk. The addition of women 
with a history of GH as well as women without any history 
of HDP, is also a strength to add broader perspective on 
this topic.
Limitations include demographic make- up of respon-
dents, with HDP participants predominantly English 
speaking and Caucasian (95%) despite the survey being 
available in Arabic and Mandarin as well as English. The 
non- HDP group (20% Asian background) had similar 
background demographics of Australian reproductive- 
aged women,26 and as HDP is more prevalent among 
the Caucasian population,27 the sample in the context 
of ethnic background actually is proportionally likely 
close to representative of Australian HDP and non- HDP 
women. However, it would have been preferable to also 
gain insight from more culturally and linguistically diverse 
groups in order to understand their knowledge base and 
address their needs within this context.
In the survey, women were asked to select their HDP 
history which was then used to group them for analysis. 
Women’s diagnosis of HDP is by self- report is a limitation, 
as some bias may be introduced through inaccurate self- 
report of diagnosis. The broad geographical range and 
anonymous nature of the survey precluded any verifica-
tion of diagnosis. However, women were provided with 
definitions of the various HDP conditions at the start of 
the survey to aid them in their self- report. Another limita-
tion is where participants were recruited from, with close 
to half either drawn from the P4 study (an Australian 
post- HDP research study) or consumer group AAPEC. 
Therefore, there may be knowledge bias in the sample 
(ie, a more knowledgeable group of participants than the 
overall HDP or non- HDP population). The women’s level 
of active engagement in pursuing further information on 
their long- term risks as well as their level of motivation 
to participate in this study, further contributes to knowl-
edge bias. The number of respondents in all included 
HDP subgroups are a small proportion of the total 
number of women experiencing HDP, which suggests 
volunteer bias and this affects generalisability. However, 
non- representative, specialised samples of women can be 
noted within most research addressing women’s knowl-
edge on long- term health after HDP.16 As even this group 
with potentially greater baseline knowledge had substan-
tive knowledge gaps, our study highlights the need for 
interventions to improve knowledge of health after HDP.
Implications
Close to two decades worth of data have been collected8 
since research on the link between HDP and increased 
CVD risk emerged in the early 2000s, with the first system-
atic review published in 2007.25 It could be expected 
that this knowledge, by now, would have been translated 
into practice and shared with HDP women, however our 
findings suggest that this is still not the case. This study 
is valuable from the public health perspective, given the 
wider context of prevalence and importance of CVD in 
women. Findings from this study and the broader study 
it is embedded in, will contribute towards the develop-
ment, application and evaluation of educational mate-
rials for women and HCP. These future projects will 
address persistent knowledge- to- practice- gaps regarding 
improving women’s cardiovascular health after HDP. 
Given the prevalence and impact of both HDP and CVD, 
this is valuable for women’s health, and public health 
more broadly.
Guidelines such as ISSHP2 and SOMANZ3 suggest 
regular follow- up after HDP as well as counselling women 
with regards to their individual long- term CVD risk. 
Although available to the public, these are not designed 
for women. Compiling suitable information for women 
would be an important step towards closing the knowl-
edge gap. It is important to establish preferred content, 
presentation and timing of education for post- HDP 
health for women as we have in this study, to maximise 
the chance that women will engage with and benefit from 
education.
CONCLUSION
This Australian survey of women’s knowledge of risks after 
HDP, found varying knowledge from the targeted groups. 
Despite ‘high’ knowledge being demonstrated regarding 
9Roth H, et al. BMJ Open 2020;10:e042920. doi:10.1136/bmjopen-2020-042920
Open access
some risks, overall significant knowledge gaps were iden-
tified for certain conditions, particularly diabetes, and 
for knowledge about the relatively early timing of when 
health risks increase after HDP. Identifying these gaps are 
important in planning tailored education for women, and 
to improve early intervention for modifiable CVD risks in 
women after HDP. Addressing these women’s preferences 
for content and to have this delivered by their health-
care provider may further lead to enhanced counselling, 
management and improved women’s health trajectories.
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